YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (HK:1558) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has entered a significant licensing agreement with Apollo Therapeutics Group Limited, granting Apollo exclusive rights to develop and commercialize APL-18881 globally, except in China. Under this agreement, the company stands to receive up to $938 million in various payments, including milestone payments and royalties based on sales outside China. This collaboration represents a strategic move for YiChang HEC to expand its market reach and capitalize on its pharmaceutical innovations.
For further insights into HK:1558 stock, check out TipRanks’ Stock Analysis page.